Study S002119

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in Reducing the Muscle Strength Loss From the GLP1 Agonist Semaglutide in Combination With Dieting in Obese and Overweight Adult Patients (OBA).

ClinicalTrials.gov record

Registration

Registration: NCT07411378
Acronym: OBA
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 164
Start: 2026-07
Primary completion: 2027-06
Lead sponsor: Biophytis
Conditions: Muscle Wasting; Obesity & Overweight; Obesity
Interventions: DRUG:BIO101; OTHER:Placebo; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Change from baseline in the knee extension strength at 21 weeks [Baseline and 21 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.